75. The state of the industry

Why do China and US have different government regulations? Why can’t we do business above the fray? These are just some of the struggles biopharma executives report impacting their business. Our guests are of the same view – the industry needs fixing. Yingke He, CEO and Co-Founder of Forecyte Bio, explains how China's industrialized experience is limited and in its early stages compared to the US. Listen to this episode to understand the industry tensions and areas showing promise. Transcript Show notes The Biopharma Resilience Index - Biopharma Resilience | Cytiva (cytivalifesciences.com) Pessimists Archive - Pessimists Archive Caesarean babies and their mother’s microbiome - 'Vaginal seeding' boosts the development of babies born by C-section | New Scientist Keywords: talent, industry, manufacturing, collaboration, pandemic, therapies, challenges, government, regulators, biopharma resilience index, policies, solutions, companies, China, genomic medicine, cell and gene therapy.

There are no comments yet.

Please log in to write the first comment.